Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

Fu, Kai; Weisenburger, Dennis D.; Choi, William W.L.; Perry, Kyle; Smith, Lynette M.; Shi, Xinlan; Hans, Christine P.; Greiner, Timothy C.; Bierman, Philip J.; Bociek, R. Gregory; Armitage, Jamés O.; Chan, Wing C.; Vose, Julie M.

doi:10.1200/jco.2007.15.9277

Cited by 287 publications

(204 citation statements)

References 61 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Other immunohistochemical defined prognostic markers such as GC phenotype, BCL2, and BCL6 have shown inconclusive results after the addition of rituximab to chemotherapy [8][9][10][11]. In the present study, no significant difference in survival was seen according to GC phenotype or BCL6 status.…”

Section: Discussioncontrasting

confidence: 36%

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Rydström

Linderoth

Nyman

et al. 2010

Leukemia & Lymphoma

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 36%

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Rydström

Linderoth

Nyman

et al. 2010

Leukemia & Lymphoma

View full text Add to dashboard Cite

“…It is well established that different genetic subgroups of DLBCL confers different prognosis; where germinal centre B-cell (GCB) lymphoma had a better prognosis than activated B cell (ABC) lymphoma (Rosenwald et al, 2002). There are evidences which demonstrated that, ABC lymphoma is associated with poorer outcome even with addition of rituximab (Lenz et al, 2007;Fu et al, 2008;Visco et al, 2013). It has also been suggested that Asian have higher rate of non-GC lymphoma compared to Western patients (Shia et al, 2005;Shiozawa et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients

Gan

Subramaniam²,

Bee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The current standard treatment for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) is rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). A significant number of patients were not treated with recommended dose of rituximab due to limited financial resources in Malaysia. This study evaluates the efficacy of R-CHOP like chemotherapy in Malaysian patients with DLBCL. Materials and Methods: The study comprised a retrospective analysis of patients with DLBCL treated at a single centre. The outcome was compared with patients who were treated with R-CHOP like and CHOP like chemotherapy. Patients who were treated with lower dose of rituximab was subanalysed for outcome. Results: A total of 86 patients who had CHOP-like chemotherapy were included. Only 39 (45%) patients had rituximab and only 12 (29%) patients had the recommended dose. The overall response (OR) and complete response (CR) rates were 88% and 81% respectively. There was no significant difference in OR and CR in patients who had rituximab and those without rituxmab. Those with International Prognostic Index (IPI) score of ≤2 had significant higher CR rate, progression free survival (PFS) and overall survival (p<0.001). Conclusions: The lack of significant improvement in CR and DFS in our patients may be due to an inadequate dose of rituximab.

show abstract

“…E tanulmány után a DLBCL-betegek kezelésében a rituximab jelentős szerepet kapott, egyre jobb eredményeket elérve a teljes túlélésben (OS) is. A két karakterisztikus alcsoportot vizsgálva egyértelmű-en bizonyítást nyert, hogy a rituximab-CHOP kezeléssel a 3 éves teljes túlélés 52%-ról 85%-ra nőtt GCB-esetekben és 33%-ról 69%-ra nőtt ABC-esetekben [8], de a kü-lönbség megmaradt a két csoport között, bár mértéke kis fokban csökkent a rituximab hatására. Ezeknek az adatoknak a birtokában ma már rutinszerűen vizsgáljuk a betegek alcsoportját, ezzel segítve a prognózisbecslést.…”

Section: öSszefoglaló Közleményunclassified

A diffúz nagy B-sejtes lymphoma modern szemlélete és kezelése

Gergely

Illés

2016

Orvosi Hetilap

View full text Add to dashboard Cite

A diffúz nagy B-sejtes lymphoma a leggyakoribb a non-Hodgkin-lymphomák között. A ciklofoszfamid-vincristinadriablastin-prednisolon kemoterápiával a betegeknek már közel 50%-a meggyógyítható volt, majd a rituximab hozzáadásával a gyógyulási arány már 60% fölé emelkedett. Ez a javulás jelentős, de további növekedést kellene elérni a betegek gyógyulási arányában. Az utóbbi években elvégzett genetikai vizsgálatok számos új, a patogenezisben is szerepet játszó és terápiás célpontként is szolgáló mutációt azonosítottak a betegségben. A diagnosztika ma már rutinszerűen alkalmazza a 18-fluoro-deoxi-glükóz-pozitronemissziós komputertomográfiás vizsgálatokat a Lugano klasszifikációs rendszer részeként. Ezen adatok alapján egyre pontosabban meghatározható a betegek prognózisa, és kiválaszthatók azok a betegek, akik valamelyik új, szelektíven ható gyógyszerre esetleg reagálhatnak. Mindezeknek a kérdéseknek a megválaszolása, az újabb kezelések bevezetése várhatóan a közeli jövőben tovább fogja javítani a betegek túlélési esélyeit. Az összefoglaló közlemény áttekintést ad a közelmúlt újdonságairól, kiemeli a ma használatos és javasolt kezeléseket, továbbá áttekintést ad a jelenleg kipróbálás alatt álló és bevezetendő kezelésekről is. Orv. Hetil., 2016, 157(31), 1232-1241. Kulcsszavak: lymphoma, DLBCL, kezelés Recent advances in the understanding and treatment of diffuse large B-cell lymphomaDiffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma. Using the conventional cyclophosphamide adriablastin vincristin prednisolon polychemotherapy about 50% of the patients were cured. The addition of rituximab to the regimen increased the cure rate to 60%. This is a major improvement, however, further advance is still needed to increase the cure rate. The extensive genetic testing performed recently revealed several important pathognomic mutations as potential targets in this disease. Routine diagnosis of patients now includes the use of 18 Fluor-deoxy-glucose positron emission computer tomography, according to the recent Lugano classification system. With all these data we can better predict the prognosis of patients, and we can select candidates for novel targeted therapies as well. Answering these questions, and utilizing novel therapies possibly will further increase the cure rate in the near future. This paper summarizes current diagnostic and therapeutic approaches and describes recent understanding in the mutations and pathognomic changes resulting in the disease. The authors also summarize the data available on experimental therapies possibly entering clinical pratice in the forthcoming years. Keywords: lymphoma, DLBCL, treatmentGergely, L., Illés, Á. [Recent advances in the understanding and treatment of diffuse large B-cell lymphoma]. Orv. Hetil., 2016, 157(31), 1232-1241. (Beérkezett: 2016 elfogadva: 2016. május Rövidítések 18 FDG = 18-fluoro-deoxi-glükóz; ABC = aktivált B-sejtes; ADCC = antitest-közvetített sejt mediálta citotoxicitás; antiHBc = hepatitis B-vírus-mag-antigén elleni ellenanyag; ...

show abstract

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

Abstract: In this retrospective study, we have shown that the subclassification of DLBCL on the basis of the cell of origin continues to have prognostic importance in the rituximab era.

Cited by 287 publications

References 61 publications

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients

A diffúz nagy B-sejtes lymphoma modern szemlélete és kezelése

Contact Info

Product

Resources

About